Review



quantikine human vegf d immunoassay kit  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    R&D Systems quantikine human vegf d immunoassay kit
    Quantikine Human Vegf D Immunoassay Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 280 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/quantikine+human+vegf+d+immunoassay/Human+VEGF-D+Quantikine+ELISA+Kit/pmc13037264-251-12-17
    Average 95 stars, based on 280 article reviews
    quantikine human vegf d immunoassay kit - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    other:

    Article Title: Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial
    Article Snippet: Reagents included in the Quantikine Human VEGF-D Immunoassay (R&D Systems, Minneapolis, MN, USA) were used in measurements.

    Article Title: Potential role for vascular endothelial growth factor-D as an autocrine factor for human gastric carcinoma cells.
    Article Snippet: We used the Quantikine Human VEGF-D Immunoassay (R&D Systems) according to the manufacturer’s instructions to measure VEGF-D levels.

    Enzyme-linked Immunosorbent Assay:

    Article Title: Use of Quantitative CT Analysis to Evaluate the Degree of Lung Destruction in Lymphangioleiomyomatosis
    Article Snippet: .. Serum VEGF-D levels were measured using the Quantikine Human VEGF-D Immunoassay (R&D Systems; Minneapolis, MN) according to the manufacturer’s instructions by enzyme-linked immunosorbent assay (ELISA). ..

    Modification:

    Article Title: Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis
    Article Snippet: VEGF-D testing was done in a College of American Pathologists (CAP)/Clinical Laboratory Improvement Amendments (CLIA)-accredited laboratory, by technicians masked to treatment assignment and clinical data. .. A modified form of the Quantikine Human VEGF-D Immunoassay (R&D Systems, Minneapolis, MN, USA) was used for the measurements. ..

    Centrifugation:

    Article Title: Serum Vascular Endothelial Growth Factor-D Prospectively Distinguishes Lymphangioleiomyomatosis From Other Diseases
    Article Snippet: .. Serum samples were obtained in serum separator tubes and allowed to clot for 30 min prior to centrifugation at 3,500 rpm for 10 min. VEGF-D levels were evaluated using the Quantikine Human VEGF-D Immunoassay (R&D Systems; Minneapolis, MN) according to the manufacturer’s instructions. .. Results were quantified using the chromogenic substrate tetramethylbenzidine and analysis with a microtiter plate spectrophotometer (Perkin Elmer; Waltham, MA) at wavelength of 450 nm, with correction at 570 nm.

    Laser Capture Microdissection:

    Article Title: Generalised mosaicism for TSC2 mutation in isolated lymphangioleiomyomatosis
    Article Snippet: .. Testing was performed either as a College of American Pathologists/Clinical Laboratory Improvement Amendments-compliant test (Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA) or in a research setting using the Quantikine Human VEGF-D Immunoassay (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions, while blinded to other clinical information and the genetic analyses. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIGURE 1 caption a7 Clinical characteristics of lymphangioleiomyomatosis (LAM) cohort and patient with generalised TSC2 mosaicism. a) Current age distribution for 61 LAM patients (median 49 years). b) Serum vascular endothelial growth factor (VEGF)-D concentrations for 55 out of 61 LAM patients (median 755 ng·μL −1 ). c) Number of patients with angiomyolipoma. d) Forced expiratory volume in 1 s (FEV 1 ) for 60 of 61 LAM patients (median 82% pred). e) Diffusing capacity of the lung for carbon monoxide ( D LCO ) for 45 of 61 LAM patients (median 76% pred). f) Number of patients with retroperitoneal lymphangioleiomyoma. a, b, d and e) Median is indicated by the horizontal line. ..



    Similar Products

    quantikine human vegf d immunoassay kit  (R&D Systems)
    95
    R&D Systems quantikine human vegf d immunoassay kit
    Quantikine Human Vegf D Immunoassay Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/quantikine+human+vegf+d+immunoassay/Human+VEGF-D+Quantikine+ELISA+Kit/pmc13037264-251-12-17
    Average 95 stars, based on 1 article reviews
    quantikine human vegf d immunoassay kit - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    quantikine human vegf immunoassay kit  (R&D Systems)
    95
    R&D Systems quantikine human vegf immunoassay kit
    Quantikine Human Vegf Immunoassay Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/quantikine+human+vegf+d+immunoassay/Human+VEGF-D+Quantikine+ELISA+Kit/us12478615-643-9-14
    Average 95 stars, based on 1 article reviews
    quantikine human vegf immunoassay kit - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    human vegf a immunoassay  (R&D Systems)
    95
    R&D Systems human vegf a immunoassay
    Human Vegf A Immunoassay, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/quantikine+human+vegf+d+immunoassay/Human+VEGF-D+Quantikine+ELISA+Kit/10__7554_slash_elife__96941-307-5-11
    Average 95 stars, based on 1 article reviews
    human vegf a immunoassay - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    quanikine human vegf immunoassay elisa kit  (R&D Systems)
    95
    R&D Systems quanikine human vegf immunoassay elisa kit
    Fig. 1. (A) Study design for the ectopic model of bone formation; scale bar = 1 mm. (B) Assessment of <t>VEGF</t> expression and incorporation into the fibrin matrices in vivo . Immunostaining for VEGF-A (VEGF, in green), human nuclei (HuNu, in red) and nuclei (DAPI, in blue) of constructs after 1 week of in vivo implantation; (C-F) Assessment of angiogenesis in vivo . (C) Immunostaining of endothelium (CD31, in red) and nuclei (DAPI, in blue) of constructs after 1, 4 and 8 weeks of in vivo implantation. (D-F) Quantification of induced angiogenesis. VLD = vessel length density, expressed as millimeters of vessel length per square millimeter of tissue area (mm/mm 2 ), in constructs after 1 (D), 4 (E) and 8 (F) weeks of in vivo implantation. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Scale bar = 100 μm.
    Quanikine Human Vegf Immunoassay Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/quantikine+human+vegf+d+immunoassay/Human+VEGF-D+Quantikine+ELISA+Kit/pm35835287-95-42-48
    Average 95 stars, based on 1 article reviews
    quanikine human vegf immunoassay elisa kit - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    immunoassay human vegf d quantikine elisa  (R&D Systems)
    94
    R&D Systems immunoassay human vegf d quantikine elisa
    Fig. 1. (A) Study design for the ectopic model of bone formation; scale bar = 1 mm. (B) Assessment of <t>VEGF</t> expression and incorporation into the fibrin matrices in vivo . Immunostaining for VEGF-A (VEGF, in green), human nuclei (HuNu, in red) and nuclei (DAPI, in blue) of constructs after 1 week of in vivo implantation; (C-F) Assessment of angiogenesis in vivo . (C) Immunostaining of endothelium (CD31, in red) and nuclei (DAPI, in blue) of constructs after 1, 4 and 8 weeks of in vivo implantation. (D-F) Quantification of induced angiogenesis. VLD = vessel length density, expressed as millimeters of vessel length per square millimeter of tissue area (mm/mm 2 ), in constructs after 1 (D), 4 (E) and 8 (F) weeks of in vivo implantation. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Scale bar = 100 μm.
    Immunoassay Human Vegf D Quantikine Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/quantikine+human+vegf+d+immunoassay/Human+VEGF+Quantikine+QuicKit+ELISA/pmc09026339-156-12-17
    Average 94 stars, based on 1 article reviews
    immunoassay human vegf d quantikine elisa - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    quantikine human vegf d immunoassay  (R&D Systems)
    93
    R&D Systems quantikine human vegf d immunoassay
    Fig. 1. (A) Study design for the ectopic model of bone formation; scale bar = 1 mm. (B) Assessment of <t>VEGF</t> expression and incorporation into the fibrin matrices in vivo . Immunostaining for VEGF-A (VEGF, in green), human nuclei (HuNu, in red) and nuclei (DAPI, in blue) of constructs after 1 week of in vivo implantation; (C-F) Assessment of angiogenesis in vivo . (C) Immunostaining of endothelium (CD31, in red) and nuclei (DAPI, in blue) of constructs after 1, 4 and 8 weeks of in vivo implantation. (D-F) Quantification of induced angiogenesis. VLD = vessel length density, expressed as millimeters of vessel length per square millimeter of tissue area (mm/mm 2 ), in constructs after 1 (D), 4 (E) and 8 (F) weeks of in vivo implantation. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Scale bar = 100 μm.
    Quantikine Human Vegf D Immunoassay, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/quantikine+human+vegf+d+immunoassay/Quantikine+Immunoassay+Control+Group+239+for+Human+VEGFR1/ppr0231907-65-7-11
    Average 93 stars, based on 1 article reviews
    quantikine human vegf d immunoassay - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 1. (A) Study design for the ectopic model of bone formation; scale bar = 1 mm. (B) Assessment of VEGF expression and incorporation into the fibrin matrices in vivo . Immunostaining for VEGF-A (VEGF, in green), human nuclei (HuNu, in red) and nuclei (DAPI, in blue) of constructs after 1 week of in vivo implantation; (C-F) Assessment of angiogenesis in vivo . (C) Immunostaining of endothelium (CD31, in red) and nuclei (DAPI, in blue) of constructs after 1, 4 and 8 weeks of in vivo implantation. (D-F) Quantification of induced angiogenesis. VLD = vessel length density, expressed as millimeters of vessel length per square millimeter of tissue area (mm/mm 2 ), in constructs after 1 (D), 4 (E) and 8 (F) weeks of in vivo implantation. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Scale bar = 100 μm.

    Journal: Acta biomaterialia

    Article Title: Robust coupling of angiogenesis and osteogenesis by VEGF-decorated matrices for bone regeneration.

    doi: 10.1016/j.actbio.2022.07.014

    Figure Lengend Snippet: Fig. 1. (A) Study design for the ectopic model of bone formation; scale bar = 1 mm. (B) Assessment of VEGF expression and incorporation into the fibrin matrices in vivo . Immunostaining for VEGF-A (VEGF, in green), human nuclei (HuNu, in red) and nuclei (DAPI, in blue) of constructs after 1 week of in vivo implantation; (C-F) Assessment of angiogenesis in vivo . (C) Immunostaining of endothelium (CD31, in red) and nuclei (DAPI, in blue) of constructs after 1, 4 and 8 weeks of in vivo implantation. (D-F) Quantification of induced angiogenesis. VLD = vessel length density, expressed as millimeters of vessel length per square millimeter of tissue area (mm/mm 2 ), in constructs after 1 (D), 4 (E) and 8 (F) weeks of in vivo implantation. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Scale bar = 100 μm.

    Article Snippet: 1 ml f medium was harvested from VEGF-expressing BMSC in one 60- m dish, following a 4h incubation at 37 °C, filtered and analyzed n duplicate. hVEGF 165 production by BMSC and VEGF-expressing MSC was quantified in cell culture supernatants using a Quanikine human VEGF immunoassay ELISA kit (R&D Systems Europe, bingdon, UK).

    Techniques: Expressing, In Vivo, Immunostaining, Construct